Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report Meeting Abstract


Authors: Conlin, A. K.; Seidman, A. D.; Moynahan, M. E.; Traina, T.; Mace, J. R.; Meiri, E.; Bach, A.; Edwards, C.; Hudis, C. A.
Abstract Title: Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: An initial interim safety report
Meeting Title: 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 25
Issue: 18 Suppl.
Meeting Dates: 2007 Jun 1-5
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2007-06-20
Start Page: 58s
Language: English
ACCESSION: WOS:000455043700243
PROVIDER: wos
Notes: Meeting Abstract: 1104 -- Source: Wos
MSK Authors
  1. Andrew D Seidman
    254 Seidman
  2. Mary Ellen Moynahan
    100 Moynahan
  3. Clifford Hudis
    848 Hudis
  4. Ariadne Bach
    56 Bach
  5. Alison Katherine Conlin
    18 Conlin
  6. Tiffany A Traina
    154 Traina